Endocrine Abstracts

The aim of investigation to study of optimization of treatment of women of childbearing age with metabolic syndrome.

Material and methods: Under supervision were 20 women with a metabolic syndrome who applied for infertility in Center of Endocrinology from 2014–2015. The control group consisted of 20 women without obesity and without disturbances of the menstrual cycle. The age of patients ranged from 20 to 39 years and averaged 28.3±0.64 years. All patients underwent a set of studies, including General clinical (General blood and urine analysis), biochemical (blood glucose, glucose tolerance test), hormonal (LH, FSH, prolactin, estradiol, progesterone, free testosterone, dehydroepiandrostenedione (DHEA), 17-oxyprogesterone (17 OKS), antimuller hormone (AMG), insulin on day 14 of the cycle), determination of cortisol in the blood and free cortisol in the daily urine. Patients to decrease body mass was appointed non-pharmacological and etiopathogenetic therapy. Etiopathogenetic therapy included therapy for 6 months: was assigned to a combination Metformin 1000 mg per day + veroshpiron 50 mg twice a week + lodmarin 100 mg in the morning + levothyroxine 50 mg in the morning + antiandrogens (Yarina, Jess, dexamethasone, etc.)+ antidepressants courses (amitriptillin, rexetin, etc.).

Results: It was found that after 6 months after treatment, patients had a significant decrease in BMI of 1 and 2 degrees after 6 months of treatment. In addition, fertility recovery and pregnancy were achieved in patients in 19.5% of cases (10 patients).

Summary: Thus, the inclusion of the drug ‘Siofor’ (Metformin) in the traditional treatment of patients with obesity of different groups contributes to a significant improvement in clinical indicators - a decrease in BMI, which indirectly indicates that in the study groups of women obesity is one of the manifestations of the metabolic syndrome.